Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma × imgatuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Non-Squamous Non-Small Cell Lung Cancer 2 Neoplasms 2 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Carcinoma 1

Interventions

Carboplatin 30 Cisplatin 23 pembrolizumab 22 Paclitaxel 21 Pemetrexed 20 Gemcitabine 10 osimertinib 9 durvalumab 9 Nivolumab 9 130-nm albumin-bound paclitaxel 8 Sunitinib 7 Sorafenib 7 Fluorouracil 7 Everolimus 7 Docetaxel 7 Cetuximab 6 Axitinib 6 epothilone B 5 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5 volociximab 4 trebananib 4 reolysin 4 catumaxomab 4 cabozantinib 4 atezolizumab 4 Radiotherapy 4 vosaroxin 3 liposomal doxorubicin 3 lenvatinib 3 capmatinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04985825 2022-09-13

I-PACE

Centessa Pharmaceuticals plc

Phase 2 Withdrawn

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡